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Nan Jiang, Connie Qi, Young Trieu, Donna Reece, Hong ChangThe majority of patients with multiple myeloma (MM) have intact immunoglobulin, but in a subset of patients
(15%), their tumors produce monoclonal light chains only (LCO). Although specific genomic aberrations
have emerged as a major prognostic factor in MM, their incidence and prognostic impact on LCO myeloma
patients are not clear. We therefore investigated a cohort of 86 LCO MM cases diagnosed and treated with
autologous stem cell transplantation at our institution. Overall, genomic risk factors del(13q), del(17p),
t(4;14), 1p loss, and 1q21 gain were detected by cytoplasmic fluorescence in situ hybridization (cIg-FISH)
in 40.6%, 18.5%, 11.9%, 18.8%, and 25% of the cases, respectively. Patients with del(13q) and 1q gains had
a significantly shorter overall survival (OS) (median 80.4 vs 56.2 months, P 5 .021; median 77.9 vs 26.9
months, P 5 .006, respectively) and shorter progression-free survival (PFS) (median 33.4 vs 15.8 months,
P 5 .002; median 33.4 vs 19.1 months, P 5 .011, respectively) than those without the genetic abnormalities.
In addition, 1p loss was significantly associated with shorter PFS (median 37.9 vs 18.2 months, P 5 .001).
There was no significant difference in PFS or OS in patients with or without t(4;14) or del(17p). On multi-
variate analysis, del(13q) was an independent prognostic factor for PFS and OS.
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Multiple myeloma (MM) is characterized by an
expansion of clonal plasma cells with production of
monoclonal immunoglobulin. Even though the ma-
jority of MM cases are characterized by the detection
of intact immunoglobulin—with 2 heavy chains and
2 light chains—in the serum, about 15% of the
patients present only immunoglobulin light chains
detected either in the urine or serum or both. These
patients are designated as having light-chain-only
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formation are not clearly understood. Szcepanski
et al. [1] suggested that the absence of heavy chain
was related to defects in DNA rearrangements.
Magrangeas et al. [2] further extended the understand-
ing of the molecular bases of LCO MM by using
fiber-fluorescent in situ hybridization technique.
Their results demonstrated that patient samples and
myeloma cell lines secreting heavy chains present
a legitimate functional IgH rearrangement, whereas
LCOMM does not display a functional IgH recombi-
nation. Interestingly, most LCO MM cases presented
1 IgH allele with a germline configuration, the second
allele being usually involved in an illegitimate recom-
bination such as translocations. Thus, the absence of
legitimate IgH rearrangement at the DNA level in
LCO MM could reflect possible abnormalities in the
IgH gene recombination during B cell maturation [2].
Although specific genomic aberrations, including
del(13q), t(4;14), del(17p), and chromosome 1 abnor-
malities (1p losses or 1q gains), have emerged as major
prognostic factors in common MM [3,4], the genomic
changes and their prognostic impact in LCO patients
have not been elucidated. In this study, we have
systematically analyzed the impact of recurrent
Biol Blood Marrow Transplant 17:1790-1795, 2011 1791Patients with Light-Chain-Only MM Undergoing ASCTchromosomal aberrations on the clinical outcomes in
an LCO MM patient cohort in order to determine
whether these genetic risk stratifications used in
common MM are also applicable in LCO MM cases.DESIGN AND METHODS
Patients
A total of 86 patients with LCO MM identified
by urine and serum immunoelectrophoresis were
included in this study. They were treated with autolo-
gous stem cell transplant (ASCT) at University Health
Network. All but 6 patients received 4 to 5 cycles of
vincristin, adriamycin, and dexamethasone (VAD) as
induction and 1 course of melphalan 200 mg/m2
followed by ASCT, whereas 6 of the more recently
treated patients were induced with bortezomib com-
binations. All patients were mobilized following
diagnosis or after a first-line therapy. The induction
regimen is followed by stem cell mobilization with
cyclophosphamide 2.5 g/m2 and granulocyte-colony
stimulating factor (G-CSF; 10 mg/kg). The median
posttransplantation follow-up was 36.5 months. The
clinical and laboratory features at diagnosis are sum-
marized in Table 1.
Interphase Fluorescence in Situ Hybridization
(FISH)
Following institutional research review board
approval, bone marrow aspirates were obtained from
patients with active LCO MM before VAD induction
and ASCT. Cytoplasmic light-chain immunofluores-
cence with simultaneous FISH analysis (cIg-FISH)
was performed on fixed mononuclear cells prepared
on cytospin slides as previously described [5,6]. Clonal
plasma cells were identified by light-chain im-
munofluorescence and their nuclear hybridization
pattern evaluated on an epifluorescence microscope
using an imaging system (Applied Imaging, Santa
Clara, CA).
The cIg-FISH methods with appropriate probes
for evaluating deletions of 13q and del(17p), t(4;14),
and 1q gains and 1p loss were described previously
[3,5,6]. At least 200 plasma cells were scored for
each FISH signal to estimate the prevalence of each
molecular cytogenetic abnormality. The positive
cutoff level was established as exceeding 10% for each
FISH probe set.
Statistical Analysis
The Fisher exact and chi-square tests were used
and survival calculated using the Kaplan-Meier
method. Progression-free survival (PFS) was calcu-
lated from the transplantation date to the date of death,
progression, or last follow-up. Overall survival (OS)
was calculated from the transplantation date to thedate of death or last follow-up. Differences between
survival curves were analyzed by log-rank test.
Multivariate analyses were applied using the Cox-
proportional hazard regression model. Hazard ratio
(HR) and 95% confidence interval (CI) were estimated
from the multivariate model. Results were considered
significant if the P value was #.05. The statistical
analysis was performed using SPSS 15.0 (SPSS, Inc.,
Chicago, IL).RESULTS
Clinical Features
There were 51 males and 35 females with a median
age of 54 years (range: 30-70 years) at diagnosis. In all,
79 (91.7%) of 86 LCO patients were younger than 65
years of age. According to the International Staging
System (ISS), 43 patients were in stage I, 11 in stage
II, and 19 in stage III, while 13 patients could not be
classified because of missing b2-microglobulin and/or
albumin data; 20.0% of LCO patients had a high
incidence of renal impairment with elevated serum
creatinine of .177 mmol/L. Fifty-seven (66%) had
free k LC type, whereas the remaining 29 (34%) of
the patients produced l LC (Table 1).
Genetic Abnormalities Detected by cIg-FISH
Chromosomal aberrations were assessed in 75
(87.2%) of 86 patients. Interphase-FISH analysis on
plasma cells revealed del(13q) in 26 (40.6%) of 64
patients, as well as del(17p) in 12 (18.5%) of 65, the
IgH-translocations t(4;14) in 8 (11.9%) of 67, 1p loss
in 13 (18.8%) of 69, and gains of chromosomes 1q in
15 (25%) of 60 patients. Of 54 patients with the status
of all 5 genetic factors available, 1 (1.9%) had coexis-
tence of 5 genetic abnormalities, 4 (7.4%) had 4,
3 (5.7%) had 3, and 9 (17%) had 2, and 17 (31%)
had 1 only. No genetic abnormalities were detected
in 20 (37%) patients (Figure 1).
Correlation between Genetic Abnormalities
with Clinical Features and Outcome in LCOMM
The overall response rates were similar in patients
with and without the 5 genetic abnormalities tested
by cIg-FISH. The PFS and OS for patients with
each genetic aberration are outlined in Table 2.
The median PFS was 24.8 months (95% CI: 18.4–
31.3), and the OS was 68.8 months (95% CI: 50.2-
87.5). Patients with del(13q) had a significantly shorter
PFS (15.8 vs 33.4 months, P 5 .002) (Figure 2A) and
OS (56.2 vs 80.4 months, P 5 .021) (Figure 2B). Sim-
ilarly, when chromosome 1 abnormalities were exam-
ined, patients with 1q21 gains had a significantly
shorter PFS (19.1 vs 33.4 months, P 5 .011)
(Figure 2C) and OS (26.9 vs 77.9 months, P 5 .006)
(Figure 2D), whereas patients with 1p loss had a shorter
Table 1. Characteristics of the Cohort of 86 Multiple Mye-
loma Patients with Autologous Stem Cell Transplant
Characteristics
Median (Range)
All Patients
(n 5 86)
Age (years), median (range) 54 (30-70)
Sex (F/M) 35/51
ISS, n (%), n 5 73
I, n (%) 43 (58.9)
II, n (%) 11 (15.1)
III, n (%) 19 (26.0)
Hb, g/dL, n 5 82, median (range) 121.5 (54-162)
Calcium level, mmol/L, median (range) 2.35 (1.62 -3.82)
CRP level, mg/L, median (range) 6 (3-4910)
b2-microglobulin, mmol/L, median
(range)
228 (2.65-7270)
Albumin, g/dL, median (range) 4.3 (3.1 -5.0)
Creatinine, mmol/L, median (range) 89 (40-1409)
Paraprotein, n (%)
Kappa light chains 57 (66.6)
Lambda light chains 29 (33.4)
del(13q) deletion, n 5 64, n (%)
Negative 38 (59.4)
Positive 26 (40.6)
del(17p), n 5 65, n (%)
Negative 53 (81.5)
Positive 12 (18.5)
t(4:14), n 5 67, n (%)
Negative 59 (88.1)
Positive 8 (11.9)
del(1p21), n 5 69, n (%)
Negative 56 (81.2)
Positive 13 (18.8)
1q21 gains, n 5 60, n (%)
Negative 45 (75)
Positive 15 (25)
Response rates to stem cell transplant therapy, n 5 65
CR + VGPR 23%
$PR 83%
ISS indicates International Staging system; CR, complete remission;
VGPR, very good partial remission; PR, partial remission.
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In contrast, del(17p) and translocation t(4;14) did not
affect prognosis (data not shown).
On univariate analysis, none of the clinical labora-
tory parameters was statistically significant. Multivar-
iate analysis, including all 5 genetic risk factors,
confirmed that only del(13q) was an independent
adverse prognostic factor for PFS (P 5 .011) and
OS (P 5 .045).DISCUSSION
To the best of our knowledge, this is the first study
that comprehensively evaluated molecular cytogeneticFigure 1. Overlap of clg-FISH abnormalities. Each column represents an indi
represents the presence of a clg-FISH abnormality.aberrations in LCO MM. In our cohort of 86 patients
with LCO MM whose bone marrow plasma cells
were subjected to cIg-FISH testing, we demonstrated
that LCO MM had similar observed incidents of the
5 genetic abnormalities to common MM [3,4,7].
Among potentially significant cytogenetic prognostic
factors, we found that t(4;14) and del(17p) were not
significantly associated with survival in our LCO
cohort. The lack of a statistically significant
difference is unclear but may be because of the
heterogeneity of t(4;14) and del(17p)’s prognostic
impact in MM, or because of our limited sample size
or follow-ups. For instance, Moreau et al. [8] found
that in a subgroup of MM patients with t(4;14) that
concomitantly presents both low serum beta-2 albu-
min (Sb2M) (\339 mmol/L) and high hemoglobin
(Hb) levels ($10 g/L) had better survival outcome
than the subgroup that concurrently expresses high
Sb2M and low Hb levels. This association with
Sb2M and Hb was also seen in patients with del(17p)
[7,9]. Thus, we further evaluated t(4;14) and del(17p)
in the context of other parameters. However, when
we coupled t(4;14) or del(17p) with Sb2M and Hb,
we did not observe a significant correlation with
poor PFS (P 5 .806 and P 5 .881) or with OS (P 5
.458 and P 5 .583).
The most important finding of this study is the
potential adverse prognostic impact that del(13q) and
chromosome 1 abnormalities (1p loss and 1q gains)
had on the LCO MM survival. Using cIg-FISH, we
found that del(13q) was a significant adverse prognos-
tic factor for both PFS and OS in our LCO cohort.
Because our finding of del(13q) is statistically signifi-
cant when detected by interphase FISH, metaphase
chromosome karyotyping, which usually contains
a greater prognostic significance for del(13q) [4], is
not necessary. There has also been controversy regard-
ing the prognostic significance of del(13q) in MM.
This chromosomal aberration was one of the first es-
tablished genetic prognostic factors [4,10]. However,
it appears that the adverse prognosis previously
thought to be conferred by this deletion is in fact due
to its association with other adverse genetic markers,
such as t(4;14) or 17p deletions, suggesting that
del(13q) on its own may not affect survival [4,11].
However, in our cohort, the aforementioned factors
were not found to be significantly associated withvidual patient. Each row indicates a specific abnormality. The pink color
Table 2. PFS and OS in LCO MM According to Cytogenetic Abnormalities
Cytogenetic
Abnormalities
Median PFS (Months)
P
Median OS (Months)
PNeg Pos Neg Pos
del (13q) 33.4 (n 5 37) 15.8 (n 5 24) .002 80.4 (n 5 38) 56.2 (n 5 26) .021
del(17p) 25.4 (n 5 50) 15.8 (n 5 12) .089 77.9 (n 5 53) 56.2 (n 5 12) .236
t(4;14) 29.4 (n 5 56) 21.4 (n 5 8) .223 68.8 (n 5 59) not reached (n 5 8) .787
del(1p21) 37.9 (n 5 52) 18.2 (n 5 13) .001 68.8 (n 5 56) 80.4 (n 5 13) .26
1q21 gains 33.4 (n 5 41) 19.1 (n 5 15) .011 77.9 (n 5 45) 26.9 (n 5 15) .006
Biol Blood Marrow Transplant 17:1790-1795, 2011 1793Patients with Light-Chain-Only MM Undergoing ASCTpoor survival in univariate analysis. Furthermore,
when we conducted the multivariate analysis
adjusting for all the tested genetic abnormalities,
del(13q) retained its prognostic significance in both
PFS and OS. On multivariate analysis, the HR for
death for patients with this abnormality was 2.73
times (for PFS) and 3 times (for OS) that of the other
patients without this abnormality. Thus, our data
suggests that del(13q) is an important independent
adverse prognostic factor in LCO MM and plays
a possible role in the progression of the disease in
LCO MM. This observation should be confirmed in
a larger cohort.
Chromosome 1 abnormalities (1q gain or 1p loss)
are the most common structural aberration in com-
monMM, found in up to 48% of abnormal metaphase
karyotypes [12]. Both comparative genomic hybrid-
ization (CGH) and FISH indicate 1q is amplified
in approximately 45% of common MM cases and
most consistently involves gains of 1q21 [13-17]. In
addition, we and other investigators showed that
gains of 1q21 were not only associated with the
overexpression of the CKS1B gene located at
1q21.3, but also with disease progression and poor
survival in MM [18-21]. In this study, we have
further confirmed that 1q21 gain was significantly
associated with inferior PFS and OS in LCO MM.
To evaluate the prognostic relevance of 1p loss,
we used a probe within the minimal common deleted
region on chromosome 1p (1p12-1p21.1), as our pre-
vious studies indicated that genomic loss at 1p21 is
an independent poor prognostic factor for PFS and
OS in MM [3,22]. We found that 1p21 loss was
associated with a shorter PFS but not a shorter OS in
LCO MM. However, different deleted regions of 1p
are reportedly associated with adverse prognosis in
common MM patients. Leone et al. [23] reported
that CDKN2C (p18), a gene located on 1p32, corre-
lated with poor survival, whereas by array CGH,
Chng et al. [24] proposed that 1p31-32 loss was asso-
ciated with shorter OS. Therefore, further studies
should include other regions of 1p in the context of
LCO MM to elucidate its prognostic relevance.
Considering the clinical features in our LCO MM
patients relative to that found among patients with
common MM, a higher serum albumin level was the
major difference between our LCO cohort andcommon MM groups. In our LCO cohort, we found
95% had serum albumin concentrations .3.5g/dL;
whereas, Drayson et al. [25] and Nair et al. [26] found
about 34% and 25% in their common MM groups,
respectively.Onepossible explanation for this difference
is that the IgA and IgGparaproteins can cause high total
serum protein levels and a compensatory reduction in
albumin concentration. Therefore, it was not surprising
that 3-fold as many LCO patients as common MM
patients had normal serum albumin levels.
In this study, we demonstrated that del(13q) may
be an important prognostic factor in LCO MM.
However, because the impact of novel therapies is
minimal in this study (as only 6 patients who received
bortezomib-based induction therapy), further trials
should be performed to assess the potential impact of
novel therapeutic strategies on survival outcomes in
the LCO MM group. Currently, conventional treat-
ments, such as VAD induction therapy, are being grad-
ually replaced by combinations using novel agents
(bortezomib, thalidomide, or lenalidomide) [27].These
new combinations are superior to classical chemother-
apy regimens in terms of remission rates, PFS, and OS
[27]. Although the optimal treatment in LCO MM is
unclear, studies that assessed the effectiveness of novel
agents in common MM may be used as a reference.
Indeed, preliminary results with bortezomib or lenali-
domide indicate that these agents may overcome
some of the poor prognoses associated with del(13q),
suggesting that these two agents are attractive alterna-
tives for post-ASCT treatment in LCO MM because
they are active even in the presence of del(13q)
[28-31]. Similarly, recent analysis of a large series of
newly diagnosed MM patients receiving bortezomib-
based induction treatments showed that del(13q) alone
had no adverse effect on both PFS and OS [32], and
similar results could be seen in LCOMM group.CONCLUSION
Our analysis of cytogenetic abnormalities revealed
that del(13q) and chromosome 1 abnormalities are
significant adverse prognostic factors in LCO MM.
Our results suggest certain traditional risk factors
may not be applicable to LCO MM. Although our
study highlighted the potential prognostic relevance
Figure 2. (A) PFS in relation to del(13q) in MM patients. (B) OS in relation to del(13q) in MM patients. (C) PFS in relation to 1q21 gains in MM patients.
(D) OS in relation to 1q21 gains and MM patients. (E) PFS in relation to 1p21 deletion in MM patients.
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studies are required to confirm our observation and
to further identify genetic factors that can predict the
clinical outcomes in LCO MM patients. In addition,
future studies should also explore the value of using
bortezomib and other novel therapies in LCOMMpa-
tients with cytogenetic risk factors in order to identify
which novel therapeutic landscape is most likely to
overcome the negative prognostic impact of unfavor-
able cytogenetic abnormalities.ACKNOWLEDGMENTS
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